Companies in #Parasitic disease
Found 1 company operating in this sector.
Late clinical-stage biopharma developing therapeutic solutions for chronic diseases in eye care and beyond; lead product XDEMVY (lotilaner ophthalmic solution 0.25%) is the first and only FDA-approved treatment for Demodex blepharitis. In August 2026 it agreed to acquire Alkeus Pharmaceuticals and its Phase 3 Stargardt disease drug for $450 million.